L. Cunningham

发表

Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder.

J. Feighner, J. Ascher, J. Apter, 1994, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

L. Cunningham, 1997, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Depression in the medically ill: choosing an antidepressant.

L. Cunningham, 1994, The Journal of clinical psychiatry.

Sexual Dysfunction Associated with the Treatment of Depression: A Placebo-Controlled Comparison of Bupropion Sustained Release and Sertraline Treatment

R. Donahue, J. Ascher, S. Batey, 1999, European Neuropsychopharmacology.

Creatine Phosphokinase and Psychiatric Illness

J. Olney, R. Woodruff, C. Rich, 1974, British Journal of Psychiatry.

The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients.

Barry R. Rittberg, J. Cohn, S. Preskorn, 1996, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.

K. Weiss, Ward T. Smith, J. Horrigan, 2008, The Journal of clinical psychiatry.

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

S. Preskorn, J. Kelsey, A. Getson, 2004, Neuropsychopharmacology.

A comparison of venlafaxine, trazodone, and placebo in major depression.

B. Diamond, G. Chouinard, E. Hearst, 1994, Journal of clinical psychopharmacology.

Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder.

J. Feighner, R. Shrivastava, S. Montgomery, 2006, The international journal of neuropsychopharmacology.

Eﬃcacy and safety of 30 mg/d and 45 mg/d nemiﬁtide compared to placebo in major depressive disorder

J. Feighner, R. Shrivastava, S. Montgomery, 2006 .

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.

F. Reimherr, J. Ascher, J. Johnston, 1998, Clinical therapeutics.